GC
FOLD

Guggenheim Capital’s Amicus Therapeutics FOLD Stock Holding History

Guggenheim Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Sell
84,973
-4,207
-5% -$60.3K 0.01% 911
2025
Q4 		$1.27M Buy
89,180
+2,572
+3% +$25.3K 0.01% 824
2025
Q3 		$682K Sell
86,608
-13,882
-14% -$98.8K 0.01% 1063
2025
Q2 		$576K Buy
100,490
+15,353
+18% +$99.1K ﹤0.01% 1108
2025
Q1 		$695K Buy
85,137
+3,370
+4% +$31.2K 0.01% 1042
2024
Q4 		$770K Sell
81,767
-13,210
-14% -$137K 0.01% 1031
2024
Q3 		$1.01M Sell
94,977
-1,138
-1% -$12.4K 0.01% 1093
2024
Q2 		$953K Sell
96,115
-2,290
-2% -$23.5K 0.01% 1140
2024
Q1 		$1.16M Buy
98,405
+3,043
+3% +$38.9K 0.01% 1119
2023
Q4 		$1.35M Sell
95,362
-5,241
-5% -$59.5K 0.01% 1016
2023
Q3 		$1.22M Sell
100,603
-2,520
-2% -$32.5K 0.01% 1013
2023
Q2 		$1.3M Sell
103,123
-2,971
-3% -$35.3K 0.01% 1042
2023
Q1 		$1.18M Buy
+106,094
New +$1.31M 0.01% 1100
2022
Q3 		– Sell
-32,199
Closed -$346K – 1957
2022
Q2 		$346K Sell
32,199
-7,549
-19% -$62.2K ﹤0.01% 1724
2022
Q1 		$377K Buy
39,748
+2,993
+8% +$28.1K ﹤0.01% 1785
2021
Q4 		$425K Sell
36,755
-130,987
-78% -$1.46M ﹤0.01% 1764
2021
Q3 		$1.6M Sell
167,742
-14,183
-8% -$145K 0.01% 1164
2021
Q2 		$1.75M Sell
181,925
-4,635
-2% -$45.2K 0.01% 1169
2021
Q1 		$1.84M Buy
186,560
+45,862
+33% +$710K 0.01% 1076
2020
Q4 		$3.25M Buy
140,698
+119,126
+552% +$2.44M 0.02% 759
2020
Q3 		$305K Buy
+21,572
New +$314K ﹤0.01% 1627
2019
Q2 		– Sell
-52,777
Closed -$718K – 2130
2019
Q1 		$718K Sell
52,777
-1,777
-3% -$21.7K 0.01% 1538
2018
Q4 		$522K Sell
54,554
-223,720
-80% -$2.46M ﹤0.01% 1657
2018
Q3 		$3.36M Buy
278,274
+17,816
+7% +$249K 0.02% 952
2018
Q2 		$4.07M Buy
260,458
+33,105
+15% +$500K 0.03% 845
2018
Q1 		$3.42M Buy
227,353
+17,470
+8% +$266K 0.01% 1253
2017
Q4 		$3.02M Sell
209,883
-60,025
-22% -$825K 0.01% 1358
2017
Q3 		$4.07M Buy
269,908
+16,133
+6% +$213K 0.01% 1187
2017
Q2 		$2.56M Sell
253,775
-32,138
-11% -$259K 0.01% 1450
2017
Q1 		$2.04M Sell
285,913
-20,292
-7% -$128K 0.01% 1651
2016
Q4 		$1.52M Buy
+306,205
New +$2.12M ﹤0.01% 1877
2016
Q2 		– Sell
-299,607
Closed -$2.53M – 2896
2016
Q1 		$2.53M Buy
299,607
+8,739
+3% +$61.9K 0.01% 1419
2015
Q4 		$2.82M Buy
290,868
+138,233
+91% +$1.25M 0.01% 1367
2015
Q3 		$2.13M Buy
+152,635
New +$2.39M 0.01% 1547
2015
Q1 		– Sell
-10,054
Closed -$84K – 3047
2014
Q4 		$84K Buy
+10,054
New +$69K ﹤0.01% 2863
2014
Q3 		– Sell
-16,717
Closed -$56K – 3033
2014
Q2 		$56K Sell
16,717
-7,370
-31% -$17.3K ﹤0.01% 3070
2014
Q1 		$49K Buy
24,087
+3,823
+19% +$9.56K ﹤0.01% 3134
2013
Q4 		$47K Buy
20,264
+2,233
+12% +$4.9K ﹤0.01% 3061
2013
Q3 		$41K Buy
18,031
+4,285
+31% +$10.8K ﹤0.01% 2960
2013
Q2 		$32K Buy
+13,746
New +$42.2K ﹤0.01% 2945

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Guggenheim Capital's FOLD Position: Q1 2026 in Review

Guggenheim Capital reduced its Amicus Therapeutics (FOLD) stake by 4.7% in Q1 2026, selling an estimated $60.3K and leaving 84,973 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #911.

Guggenheim Capital first reported a position in FOLD in Q2 2013 and has held it in 40 quarters since. The position peaked at $4.07M in Q3 2017. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Guggenheim Capital held 84,973 shares of Amicus Therapeutics worth $1.23M as of Q1 2026.
  • Guggenheim Capital sold 4,207 Amicus Therapeutics shares in Q1 2026, an estimated $60.3K.
  • Amicus Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #911 holding.
  • Guggenheim Capital first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Guggenheim Capital's Amicus Therapeutics position peaked at $4.07M in Q3 2017.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.